Idioma:

mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment

Masui, Kenta ; Cavenee, Webster K. ; Mischel, Paul S.

Brain pathology (Zurich, Switzerland), 2015-11, Vol.25 (6), p.755-759 [Periódico revisado por pares]

Switzerland: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment
Autor: Masui, Kenta ; Cavenee, Webster K. ; Mischel, Paul S.
Assuntos: Brain Neoplasms - genetics ; Brain Neoplasms - metabolism ; Cancer ; drug resistance ; Drug Resistance, Neoplasm - genetics ; Drug Resistance, Neoplasm - physiology ; Genetics ; glioblastoma ; Glioblastoma - genetics ; Glioblastoma - metabolism ; Humans ; Mechanistic Target of Rapamycin Complex 1 ; Mechanistic Target of Rapamycin Complex 2 ; metabolic reprogramming ; Metabolism ; Metabolites ; Mini‐Symposium: Cancer Metabolism in Brain Tumors ; mTORC2 ; Multiprotein Complexes - genetics ; Multiprotein Complexes - metabolism ; nutrient ; TOR Serine-Threonine Kinases - genetics ; TOR Serine-Threonine Kinases - metabolism
É parte de: Brain pathology (Zurich, Switzerland), 2015-11, Vol.25 (6), p.755-759
Notas: National Institute for Neurological Diseases and Stroke - No. NS73831
National Cancer Institute - No. CA119347
Defeat GBM Research Collaborative
Ziering Family Foundation
JSPS KAKENHI - No. 15K19067
ark:/67375/WNG-SHRKGTXC-K
The Ichiro Kanehara Foundation
ArticleID:BPA12307
Ben and Catherine Ivy Foundation
The Novartis Foundation (Japan) for the Promotion of Science
Uehara Memorial Foundation
istex:5228034E7D6315B646F2D7236FA977607EC4BB6B
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Article-1
ObjectType-Feature-2
Descrição: Metabolic reprogramming is a central hallmark of cancer, enabling tumor cells to obtain the macromolecular precursors and energy needed for rapid tumor growth. Understanding how oncogenes coordinate altered signaling with metabolic reprogramming and how cancer cells harness cellular metabolism and its metabolites for their survival may yield new insights into tumor pathogenesis. Here, we review the recently identified central regulatory role for mTORC2, a downstream effector of many cancer‐causing mutations, in metabolic reprogramming and cancer drug resistance in glioblastoma. We further consider the emerging concept that mTORC2 may connect genetics with environmental alterations in brain cancer.
Editor: Switzerland: Blackwell Publishing Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 8 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment

Masui, Kenta ; Cavenee, Webster K. ; Mischel, Paul S.

Switzerland: Blackwell Publishing Ltd

Buscando em bases de dados remotas. Favor aguardar.